1	EVALUATION OF THE SAFETY AND TOLERABILITY OF EXOGENOUS
2	KETOSIS INDUCED BY ORALLY ADMINISTERED FREE BETA-
3	HYDROXYBUTYRATE IN HEALTHY ADULT SUBJECTS
4	
5	Lisa Isabel Pimentel-Suarez ^{1,2} and Luis Adrian Soto-Mota ^{1,2*}
6	
7	<i>Metabolic Diseases Research Unit. National Institute of Medical Sciences and</i>
8	Nutrition Salvador Zubiran. Mexico City, Mexico.
9	2 Tecnologico de Monterrey. School of Medicine. Mexico City, Mexico.
10	
11	* Correspondence: adrian.sotom@incmnsz.mx; 5487 0900 ext. 6321
12	
13	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

14 ABSTRACT

Beta-hydroxybutyrate (D-BHB) is a metabolite with intrinsic signalling activity that 15 has gained attention as a potentially clinically useful supplement. There are available 16 supplements for inducing ketosis: ketone salts, ketone esters, and medium-chain triglycerides. 17 Even when all of them raise the beta-hydroxybutyrate in the blood and all are safe and well 18 tolerated, they significantly differ in their safety profile, their palatability, and their price. A 19 fourth and potentially interesting option is to use biologically identical beta-hydroxybutyrate, 20 while it is already commercially available in the United States (American Ketone LLC) and 21 22 Greater China (MedPHA Ltd). However, its safety and tolerability had not yet been documented in the scientific literature. We evaluated the safety and tolerability of orally 23 administered Free D-BHB in a gender and age-balanced sample of 24 asymptomatic and 24 overtly healthy adults. No participant showed acid-base abnormalities or electrolyte 25 abnormalities. Secondary symptoms were reported after only 6.2% of all drink takes and 26 none of the reports described the symptom as "severe". The most frequently reported 27 secondary effects (19/720 or 2.6%) were gastrointestinal discomfort, headache (7/720 or 1%), 28 and loss of appetite (7/720 or 1%). No correlation between weight-adjusted dose and 29 30 frequency of secondary symptoms was observed. Free D-BHB was a safe and well-tolerated intervention for inducing sustained exogenous ketosis. Being bio-identical, salt-free, and 31 32 lacking intermediate metabolites, this form of supplementation could have a larger safety spectrum than salt or alcohol-based exogenous ketones. More research is warranted to assess 33 its clinical efficacy in those clinical scenarios in which achieving ketosis rapidly could be 34 beneficial. 35

36

37 Keywords: Exogenous ketosis; beta-hydroxybutyrate; safety; tolerability; ketone bodies

38 KEY MESSAGES

39				
40				
41	What is already known on this topic			
42	- Ketogenic supplements could be useful therapeutic tools in certain time-sensitive			
43	circumstances. A previously unexplored but attractive option is using bio-identical D-			
44	BHB.			
45	What this study adds			
46	- Diluted Free D-BHB is a safe and well-tolerated intervention for inducing sustained			
47	exogenous ketosis.			
48	How this study might affect research, practice, or policy			
49	- Being bio-identical, salt-free, further research is warranted on the potential clinical uses			
50	of Free-BHB.			

52 INTRODUCTION

53	Several ketogenic interventions have shown benefits in a wide variety of clinical
54	scenarios [1–5]. Ketosis can be induced in different ways: by 72 hours of fasting [6], with a
55	carbohydrate-restricted [7] diet, and within minutes using supplements [8]. While
56	endogenous ketosis interventions have proven useful in many illnesses such as diabetes [2],
57	psychiatric illnesses [9], migraine, [10], and cognitive decline [11], in some time-sensitive
58	clinical scenarios where ketosis could be beneficial (for example, heart failure [12] or sepsis
59	[13]) endogenous ketosis is impractical as patients cannot wait 72 hours for achieving a
60	physiologically relevant production.
61	Beta-hydroxybutyrate (D-BHB) is a metabolite with intrinsic signalling activity [14],
62	therefore, it has gained attention as a potentially clinically useful supplement. There are three
63	thoroughly studied ketone supplements for inducing ketosis: ketone salts [15-17], ketone
64	esters [18], and medium-chain triglycerides [19]. Even when they all raise the beta-
65	hydroxybutyrate in the blood and all are safe and well tolerated, they significantly differ in
66	their safety profile, palatability, and price [8,20].
67	A fourth and potentially interesting option is to use biologically identical (D-Beta-
68	hydroxybutyrate). Being salt-free and having no intermediate metabolites or precursors, it
69	could have a broader clinical reach than previous ketone supplements (e.g., patients with
70	mineral load restrictions such as those living with heart failure [12] or chronic kidney disease
71	[21,22]). While it is already commercially available in the United States (American Ketone
72	LLC) and Greater China (MedPHA Ltd), its safety and tolerability had not yet been
73	documented in the scientific literature. In this work, we evaluated the safety and tolerability
74	of Free D-BHB as a ketogenic supplement in healthy adults.

76 MATERIALS AND METHODS

This study was pre-registered in ClinicalTrials.gov on October 22nd, 2022, with the
identifier NCT05584371. Ethical approval was obtained from the Ethics Committee of the
National Institute of Medical Sciences and Nutrition Salvador Zubirán with the file code
UIE-4275-22-23-1 on September 22nd, 2022. The study workflow can be observed in Figure
1.

A gender and age-balanced sample of asymptomatic adults (most of them, healthcare 82 83 workers) without illnesses that caused acid-base imbalances were recruited and asked to ingest 10 grams of beta-hydroxybutyrate, diluted in one litre of water and sweetened with a 84 85 sugar substitute derived from the stevia plant already embedded in the preparation, every 86 morning between 9:00 and 11:00 for four weeks. Women of childbearing age were recruited only if using a long-term method of contraception including any form of hormonal 87 contraception and intrauterine devices. The exclusion criteria included adults on a ketogenic 88 diet, carbohydrate-restricted diet, or intermittent fasting. 89

90 The exogenous ketones used in our study were provided by a joint donation from 91 American Ketone LLC and MedPHA Ltd. This bio-identical D-BHB is produced with the 92 acid hydrolysis of Poly-3Hydroxy-Butyrate [23] and is available in 60 ml bottles with 10g of 93 free D-BHB each. Participants were instructed to dilute their content in 1 litre of water before 94 consuming it.

As previously used in other studies on ketone supplement studies [18], the frequency and severity of symptoms (mild, moderate, severe) were assessed every two weeks with a self-administered open questionnaire to avoid priming positive and negative symptom reports and the intervention adherence was corroborated with qualitative urinary ketone strips (calculated as the proportion of urinary ketone strips with detectable acetoacetate). Venous

blood gases were analysed at the baseline, 2 and 4 weeks later to rule out acid-base disorders. 100 All blood samples were handled and analysed at the central lab of the National Institute of 101 Medical Sciences and Nutrition Salvador Zubiran adhering to their internationally certified 102 standard operating procedures. 103 Being hemodynamically stable, and consistent with previous studies, venous blood 104 samples were preferred over arterial ones. Since acid-base analysis assumes arterial values, 105 all acid-base variables were therefore "arterialized" by adding 0.04 to the measured pH and 106 subtracting 5 from the measured pCO2 [24]. Because of Mexico City's altitude, the normal 107 range for CO2 is different than for most places in the world $(30.2 \pm 3.4 \text{ mmHg})$ [25]. 108 Data were analysed using R version 4.0.3 with R-Studio 2022.07.2+576. Blood gas 109 110 analysis was performed using CreateTableOne::CreateContTable using default parameters. 111 Individual trajectory plots were produced using Microsoft Office Excel. The sample size was calculated for achieving a balanced age and sex sample based on previously reported safety 112 and tolerability studies of ketone supplements [18]. All results are reported as mean +/-113 standard deviation and the statistical significance cut-off was p<0.05. 114 115

116 **RESULTS**

117	In total 24 adults were recruited and all of them finished their participation. Their
118	demographic characteristics by sex can be observed in Table 1.
119	No participant showed abnormalities in their vital signs or acid-base assessments in
120	any of their visits (Figure 2). Additionally, all acid-base parameters were non-significantly
121	different across all time points (Table 2). Additionally, no electrolyte abnormalities in Na, K,
122	Cl, or ionized Ca were observed (shown in the publicly available dataset).
123	Regarding tolerability and palatability, all participants responded to the self-reported
124	questionnaires at least once and had an adherence above 90%. Only 44 out of the 720 total
125	takes (6.2%) of the drink reported secondary symptoms. Of which, none of the reports
126	described the symptom as "severe", (17/720 or 2.3%) were "moderate" and the remaining
127	(27/720 or 3.9%) were "mild" (Table 3).
128	The most reported secondary effects (19/720 or 2.6%) were gastrointestinal
129	discomfort, headache (7/720 or 1%), and loss of appetite (7/720 or 1%). The rest of the
130	reported secondary symptoms were reported <1% of the time. No participant reported more
131	than 2 secondary symptoms nor the same symptom more than twice. No correlation between
132	weight-adjusted dose and frequency of secondary symptoms was observed (Figure 3).

134 DISCUSSION

135	Hereby and as observed with other formulations [16,18], exogenous ketosis with Free
136	D-BHB was safe and well tolerated. Since Free-D-BHB has some advantages over other
137	formulations, more research on its potential clinical applications is warranted.
138	For example, ketone salts may not be suitable for patients who should restrict their
139	salt intake, such as those with heart failure or kidney disease [26]. On the other hand, the
140	ketone monoester has an alcohol precursor that could limit its use in patients with liver
141	disease and has poor palatability [3,20]. More importantly, being bio-identical, it is
142	reasonable to assume that the safety and pharmacokinetic properties of Free D-BHB are
143	comparable to the endogenously produced metabolite.
144	It is worth reminding that since Mexico City is more than 2200 meters above sea
145	level, the geometrical normal values are slightly different, and it is expected to observe lower
146	CO2 and HCO3 levels in healthy individuals. This difference is relevant because clinicians
147	elsewhere could incorrectly diagnose respiratory alkalosis with CO2 values that are normal
148	for people living in Mexico City. [25] Consistently with other ketone supplement
149	formulations, even those inducing acute documented acid-base disturbances [8], the chronic
150	
	ingestion of Free D-BHB did not cause chronic acid-base or electrolyte alterations
151	ingestion of Free D-BHB did not cause chronic acid-base or electrolyte alterations [8,15,16,18].

.5 ıy, ıg ıg դ Ρ healthcare workers and adherence was above 90%, making it unlikely that the low frequency 153 of adverse effects is due to lack of adherence, and the close communication with participants. 154 Moreover, since all participants consumed the same dose but have different weights a dose/kg 155 spectrum is created allowing us to see if the frequency of adverse symptoms is more frequent 156 in leaner individuals. As with other ketogenic supplements, no correlation was observed [18]. 157

Furthermore, we examined a sample size that is comparable to what has been examined for other commercially available ketogenic compounds. However, in contrast with those studies, we were able to enlist a more diverse age and gender distribution in our study. For example, Holland et al [15], who only studied individuals between the ages of 18 and 35, and Stefan et al [17], focused exclusively on teenagers. This difference is particularly relevant as some of the potential clinical applications of exogenous ketones like heart failure [12] or cognitive decline [11] are on illnesses that are more frequent among elders.

Acid-base and blood electrolytes are the only markers that different types of 165 exogenous ketones have shown to induce changes on [8]. Therefore, when comparing studies 166 evaluating the safety of different exogenous ketones, it is important to consider that some of 167 the relevant markers, they measured are specific to the chemical nature of each supplement. 168 In other words, due to their alcohol content, liver enzyme measurements are relevant for 169 butanediol or the ketone ester but not for bioidentical BHB. Moreover, despite having used 170 BHB doses many times greater than the one we worked with, none of the exogenous ketone 171 supplements has been shown to induce detrimental changes in liver or kidney function tests 172 173 [8,10,15,16,18]. Notably, the only case where other biomarkers have been shown to change after consuming a ketone supplement, are migraine patients with baseline metabolic risk 174 175 markers, in whom these markers (i.e. C-reactive protein, cortisol insulin and thyroid markers) improved [10]. 176

On the other hand, although comparable to what has been documented with other forms of ketone supplementation [8,10,15,16,18], we should mention its follow-up time among its limitations. Additionally, is not possible to make direct comparisons about palatability between the other available ketogenic supplements, and more studies directly addressing this question are required [20].

183 CONCLUSIONS

- 184 Diluted Free D-BHB was a safe and well-tolerated intervention for inducing sustained
- 185 exogenous ketosis. Being bio-identical, salt-free, and lacking intermediate metabolites, this
- 186 form of supplementation has a larger safety spectrum than salt or alcohol-based exogenous
- 187 ketones. More research is warranted to assess its clinical efficacy in those clinical scenarios
- 188 where achieving ketosis rapidly could be beneficial.

189

DECLARATIONS

- **Funding:** The exogenous ketones used in our study were provided by a joint donation from
- 193 American Ketone LLC and MedPHA Ltd. However, the authors designed, carried out,
- analysed all data and wrote this report independently.
- **Data Availability Statement:** Anonymized data and analysis code are publicly available at:
- 196 https://github.com/AdrianSotoM/FreeBHB.
- 197 Acknowledgements: The authors thank the Central Laboratory staff at the National Institute
- 198 of Medical Sciences and Nutrition Salvador Zubiran for their invaluable support to make this
- 199 work possible.
- 200 **Conflicts of Interest:** Both authors declare they are free of any financial interests or personal
- 201 relationships that could have influenced their interpretation or reporting of these data.
- 202
- 203

204 CONTRIBUTORSHIP STATEMENT

205 LIPS recruited participants and collected data, and ASM designed the study and analysed

- 206 data. Both authors redacted this draft and approved the current version of the manuscript.
- 207
- 208

209 **REFERENCES**

- 210 1. Norwitz, N.G.; Jaramillo, J.G.; Clarke, K.; Soto, A. Ketotherapeutics for
- 211 Neurodegenerative Diseases. In International Review of Neurobiology; 2020.
- 212 2. Nicholas, A.P.; Soto-Mota, A.; Lambert, H.; Collins, A.L. Restricting Carbohydrates
- and Calories in the Treatment of Type 2 Diabetes: A Systematic Review of the Effectiveness
- of "low-Carbohydrate" Interventions with Differing Energy Levels. J Nutr Sci 2021, 10,
- 215 doi:10.1017/jns.2021.67.
- 216 3. Soto-Mota, A.; Norwitz, N.G.; Evans, R.D.; Clarke, K. Exogenous D-β-
- 217 Hydroxybutyrate Lowers Blood Glucose in Part by Decreasing the Availability of L-Alanine
- for Gluconeogenesis. Endocrinol Diabetes Metab 2022, 5, e00300, doi:10.1002/EDM2.300.
- 4. Norwitz, N.G.; Hu, M.T.; Clarke, K. The Mechanisms by Which the Ketone Body D-
- 220 β-Hydroxybutyrate May Improve the Multiple Cellular Pathologies of Parkinson's Disease.
- 221 Front Nutr 2019, 6, 63, doi:10.3389/fnut.2019.00063.
- 5. Norwitz, N.G.; Dalai, S.S.; Palmer, C.M. Ketogenic Diet as a Metabolic Treatment for
- 223 Mental Illness. Curr Opin Endocrinol Diabetes Obes 2020, 27, 269–274,
- doi:10.1097/MED.00000000000564.
- Cahill, G.F.; George, F.C. Fuel Metabolism in Starvation. Annu Rev Nutr 2006, 26, 1–
 22, doi: 10.1146/annurev.nutr.26.061505.111258.
- 227 7. Feinman, R.D.; Pogozelski, W.K.; Astrup, A.; Bernstein, R.K.; Fine, E.J.; Westman,
- E.C.; Accurso, A.; Frassetto, L.; Gower, B.A.; McFarlane, S.I.; et al. Dietary Carbohydrate
- 229 Restriction as the First Approach in Diabetes Management: Critical Review and Evidence
- 230 Base. Nutrition 2015, 31, 1–13, doi: 10.1016/J.NUT.2014.06.011.

231	8. 5	Stubbs, B.J.; Cox, P.J.; Evans, R.D.; Santer, P.; Miller, J.J.; Faull, O.K.; Magor-Elliott,
232	S.; Hiya	ma, S.; Stirling, M.; Clarke, K. On the Metabolism of Exogenous Ketones in
233	Humans	s. Front Physiol 2017, 8, 848, doi:10.3389/fphys.2017.00848.
234	9. I	Danan, A.; Westman, E.C.; Saslow, L.R.; Ede, G. The Ketogenic Diet for Refractory
235	Mental	Illness: A Retrospective Analysis of 31 Inpatients. Front Psychiatry 2022, 13, 1421,
236	doi:10.3	389/FPSYT.2022.951376/BIBTEX.
237	10. 0	Gross, E.C.; Putananickal, N.; Orsini, AL.; Schoenen, J.; Fischer, D.; Soto-Mota, A.
238	Defining	g Metabolic Migraine with a Distinct Subgroup of Patients with Suboptimal
239	Inflamm	natory and Metabolic Markers. Sci Rep 2023, 13, 3787, doi:10.1038/s41598-023-
240	28499-у	<i>.</i>
241	11. I	Myette-Côté, É.; Soto-Mota, A.; Cunnane, S.C. Ketones - Potential to Achieve Brain
242	Energy	Rescue and Sustain Cognitive Health during Aging. British Journal of Nutrition 2021.
243	12.	Nielsen, R.; Møller, N.; Gormsen, L.C.; Prof, A.; Lars,; Tolbod, P.; Nils, ; Hansson,
244	H.; Sore	ensen, J.; Hendrik, ; et al. Cardiovascular Effects of Treatment with the Ketone Body
245	3-Hydro	oxybutyrate in Chronic Heart Failure Patients Running Title: Nielsen et al.; Treating
246	Heart Fa	ailure with Ketones. Circulation 2019,
247	doi:10.1	161/CIRCULATIONAHA.118.036459.
248	13.	Soto-Mota, A.; Norwitz, N.G.; Clarke, K. Why a D-β-Hydroxybutyrate Monoester?
249	Biochen	n Soc Trans 2020, 48, 51–59, doi:10.1042/BST20190240.

- 250 14. Rojas-Morales, P.; Tapia, E.; Pedraza-Chaverri, J. β-Hydroxybutyrate: A Signaling
- 251 Metabolite in Starvation Response? Cell Signal 2016, 28, 917–923, doi:
- 252 10.1016/j.cellsig.2016.04.005.

253	15. Holland, A.M.; Qazi, A.S.; Beasley, K.N.; Bennett, H.R. Blood and Cardiovascular
254	Health Parameters after Supplementing with Ketone Salts for Six Weeks. Journal of Insulin
255	Resistance 2019, 4, 7, doi:10.4102/jir. v4i1.47.
256	16. Buga, A.; Kackley, M.L.; Crabtree, C.D.; Sapper, T.N.; Mccabe, L.; Fell, B.;
257	LaFountain, R.A.; Hyde, P.N.; Martini, E.R.; Bowman, J.; et al. The Effects of a 6-Week
258	Controlled, Hypocaloric Ketogenic Diet, With and Without Exogenous Ketone Salts, on Body
259	Composition Responses. Front Nutr 2021, 8, 618520, doi:10.3389/fnut.2021.618520.
260	17. Stefan, M.; Sharp, M.; Gheith, R.; Lowery, R.; Wilson, J.; Caprio, M. The Effect of
261	Exogenous Beta-Hydroxybutyrate Salt Supplementation on Metrics of Safety and Health in
262	Adolescents. 2021, doi:10.3390/nu13030854.
263	18. Soto-Mota, A.; Vansant, H.; Evans, R.D.; Clarke, K. Safety and Tolerability of
264	Sustained Exogenous Ketosis Using Ketone Monoester Drinks for 28 Days in Healthy
265	Adults. Regulatory Toxicology and Pharmacology 2019, 109, 104506, doi:
266	10.1016/j.yrtph.2019.104506.

267 19. St-Onge, M.-P.; Jones, P.J.H. Physiological Effects of Medium-Chain Triglycerides:
268 Potential of Obesity. Recent Advances in Nutritional Sciences 2002, 132, 329–332.

269 20. Stubbs, B.J.; Cox, P.J.; Kirk, T.; Evans, R.D.; Clarke, K. Gastrointestinal Effects of

270 Exogenous Ketone Drinks Are Infrequent, Mild and Vary According to Ketone Compound

and Dose. Int J Sport Nutr Exerc Metab 2019, 1–23, doi:10.1123/ijsnem.2019-0014.

272 21. Torres, J.A.; Kruger, S.L.; Broderick, C.; Amarlkhagva, T.; Agrawal, S.; Dodam, J.R.;

273 Mrug, M.; Lyons, L.A.; Weimbs, T. Ketosis Ameliorates Renal Cyst Growth in Polycystic

274 Kidney Disease. Cell Metab 2019, 30, 1007-1023.e5, doi: 10.1016/j.cmet.2019.09.012.

- 275 22. Rojas-Morales, P.; Pedraza-Chaverri, J.; Tapia, E. Ketone Bodies for Kidney Injury
- and Disease. Advances in Redox Research 2021, 2, 100009, doi:
- 277 10.1016/J.ARRES.2021.100009.
- 278 23. Seebach, D., Beck, A., Breitschuh, R., & Job, K. (2003). Direct Degradation Of The
- 279 Biopolymer Poly[(R)-3-Hydroxybutyric Acid] To (R)-3-Hydroxybutanoic Acid And Its
- 280 Methyl Ester. Organic Syntheses, 71. https://doi.org/10.15227/orgsyn.071.0039
- 281 24. Walkey, A.J.; Farber, H.W.; O'Donnell, C.; Cabral, H.; Eagan, J.S.; Philippides, G.J.
- 282 The Accuracy of the Central Venous Blood Gas for Acid-Base Monitoring.
- 283 http://dx.doi.org/10.1177/0885066609356164 2009, 25, 104–110,
- doi:10.1177/0885066609356164.
- 285 25. Cid-Juárez, S.; Téllez-Navarrete, N.A.; Bautista-Bernal, A.; León-Gómez, P.; Salas-
- 286 Escamilla, I.; Gochicoa-Rangel, L.; Pérez-Padilla, R. Arterial Blood Gases in Normal
- 287 Subjects at 2240 Meters Above Sea Level: Impact of Age, Gender, and Body Mass Index.
- 288 Clinical and Translational Investigation 2023, 75, doi:10.24875/RIC.22000281.
- 289 26. Borlaug, B.A. Evaluation and Management of Heart Failure with Preserved Ejection
- 290 Fraction. Nat Rev Cardiol 2020, 17, 559–573.

291

293 **TABLES**

294

Table 1. Baseline characteristics of the participants.

	Women (n = 13)	Men (n = 11)
Age (years)	42.2 ± 13.7	41.5 ± 14.7
Height (m)	1.6 ± 0.04	1.77 ± 0.04
Weight (kg)	64.3 ± 8.8	78.9 ± 14.8
Dose (mg/kg)	158 ± 20.9	129.8 ± 19.2
Body Mass Index	23.9 ± 3.2	20.9 ± 6.3

* Data are means \pm standard deviation.

295

296

297

Table 2. Acid-base analyses across all time points (arterialized values).

	Visit 1	Visit 2	Visit 3	p-value
pН	7.41 ± 0.03	7.43 ± 0.03	7.44 ± 0.03	0.19
pCO ₂	39.2 ± 4.3	38.5 ± 5.8	37 ± 4.7	0.30
HCO ⁻ 3	24.9 ± 2.6	24.8 ± 2.3	24.4 ± 1.9	0.72
* Data are means ± standard deviation. Hypothesis testing used a Kruskal-Wallis Test.				

298

299

300 301

Table 3. Secondary symptoms following each of the 720 administered ketone drinks.

Symptom	No of participants	Events* (mild/moderate)
Gastrointestinal discomfort	8	20/720 (10/10)
Loss of appetite	5	12/720 (9/3)
Headache	6	12/720 (8/4)

302 303 * Some participants recorded the same symptom more than once, so the occurrence was expressed relative to 720, the total number of drinks consumed (24 x 30 drinks).











Figure 1. Study Workflow.







315

314